Free Trial
NASDAQ:PRLD

Prelude Therapeutics (PRLD) Stock Price, News & Analysis

$6.20
0.00 (0.00%)
(As of 07/17/2024 ET)
Today's Range
$5.67
$6.68
50-Day Range
$3.32
$6.21
52-Week Range
$1.66
$6.68
Volume
447,958 shs
Average Volume
68,584 shs
Market Capitalization
$261.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.75

Prelude Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Sell
1.33 Rating Score
Upside/​Downside
23.4% Downside
$4.75 Price Target
Short Interest
Bearish
2.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Prelude Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.84) to ($1.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.18 out of 5 stars

Medical Sector

903rd out of 914 stocks

Pharmaceutical Preparations Industry

428th out of 433 stocks

PRLD stock logo

About Prelude Therapeutics Stock (NASDAQ:PRLD)

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

PRLD Stock Price History

PRLD Stock News Headlines

Prelude Therapeutics (NASDAQ:PRLD) Trading 10.6% Higher
No matter the outcome of the election, it could be a death sentence for your wealth...
In today's financial landscape, many investors are feeling disillusioned and disappointed with traditional investment options.
No matter the outcome of the election, it could be a death sentence for your wealth...
In today's financial landscape, many investors are feeling disillusioned and disappointed with traditional investment options.
Prelude Therapeutics Inc Ordinary Shares PRLD
PRLD Apr 2024 5.000 call
See More Headlines
Receive PRLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/07/2024
Today
7/17/2024
Next Earnings (Estimated)
8/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRLD
Fax
N/A
Employees
128
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.75
High Stock Price Target
$7.00
Low Stock Price Target
$3.00
Potential Upside/Downside
-23.4%
Consensus Rating
Sell
Rating Score (0-4)
1.33
Research Coverage
3 Analysts

Profitability

Net Income
$-121,830,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.32 per share

Miscellaneous

Free Float
15,653,000
Market Cap
$261.11 million
Optionable
Optionable
Beta
1.55
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Krishna Vaddi D.V.M. (Age 58)
    Ph.D., Founder, CEO & Director
    Comp: $905.92k
  • Dr. Edna Huang M.D. (Age 51)
    President & Chief Medical Officer
    Comp: $865.63k
  • Mr. Bryant David Lim J.D. (Age 53)
    Interim CFO, Chief Legal Officer & Corporate Secretary
    Comp: $586.42k
  • Ms. Aimee Crombie Ph.D.
    Senior VP and Head of Strategic Planning & Operations
  • Dr. Madhu Pudipeddi Ph.D.
    Senior Vice President of Technical Operations
  • Dr. Peggy A. Scherle Ph.D. (Age 62)
    Chief Scientific Officer
    Comp: $868.62k
  • Lindsey Trickett
    Vice President of Investor Relations
  • Ms. Michele Porreca M.B.A.
    Chief People Officer
  • Dr. Andrew P. Combs Ph.D. (Age 57)
    Executive VP & Chief Chemistry Officer
    Comp: $562.46k
  • Mr. Naveen Babbar Ph.D.
    Senior Vice President of Translation Medicine

PRLD Stock Analysis - Frequently Asked Questions

How have PRLD shares performed this year?

Prelude Therapeutics' stock was trading at $4.27 at the beginning of 2024. Since then, PRLD shares have increased by 45.3% and is now trading at $6.2050.
View the best growth stocks for 2024 here
.

How were Prelude Therapeutics' earnings last quarter?

Prelude Therapeutics Incorporated (NASDAQ:PRLD) posted its earnings results on Tuesday, May, 7th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.05.

When did Prelude Therapeutics IPO?

Prelude Therapeutics (PRLD) raised $149 million in an initial public offering on Friday, September 25th 2020. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, Goldman Sachs and BofA Securities acted as the underwriters for the IPO.

How do I buy shares of Prelude Therapeutics?

Shares of PRLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRLD) was last updated on 7/17/2024 by MarketBeat.com Staff

From Our Partners